Literature DB >> 29504482

Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults.

Cristina Tassorelli1,2, Hans-Christoph Diener3, David W Dodick4, Stephen D Silberstein5, Richard B Lipton6, Messoud Ashina7, Werner J Becker8,9, Michel D Ferrari10, Peter J Goadsby11, Patricia Pozo-Rosich12,13, Shuu-Jiun Wang14.   

Abstract

Background Quality clinical trials form an essential part of the evidence base for the treatment of headache disorders. In 1991, the International Headache Society Clinical Trials Standing Committee developed and published the first edition of the Guidelines for Controlled Trials of Drugs in Migraine. In 2008, the Committee published the first specific guidelines on chronic migraine. Subsequent advances in drug, device, and biologicals development, as well as novel trial designs, have created a need for a revision of the chronic migraine guidelines. Objective The present update is intended to optimize the design of controlled trials of preventive treatment of chronic migraine in adults, and its recommendations do not apply to trials in children or adolescents.

Entities:  

Keywords:  Chronic migraine; clinical trials; drugs; headache; preventive treatment

Mesh:

Year:  2018        PMID: 29504482     DOI: 10.1177/0333102418758283

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  76 in total

Review 1.  Is Medication Overuse Drug Specific or Not? Data from a Review of Published Literature and from an Original Study on Italian MOH Patients.

Authors:  Licia Grazzi; Eleonora Grignani; Domenico D'Amico; Emanuela Sansone; Alberto Raggi
Journal:  Curr Pain Headache Rep       Date:  2018-08-27

2.  Headache Gauge: a real-life calendar-based tool for headache monitoring.

Authors:  Raquel Gil-Gouveia; Inês Brás Marques; Elsa Paixão Parreira; Isabel Pavão Martins; António Gouveia Oliveira
Journal:  Neurol Sci       Date:  2021-02-04       Impact factor: 3.307

3.  Evaluation of green light exposure on headache frequency and quality of life in migraine patients: A preliminary one-way cross-over clinical trial.

Authors:  Laurent F Martin; Amol M Patwardhan; Sejal V Jain; Michelle M Salloum; Julia Freeman; Rajesh Khanna; Pooja Gannala; Vasudha Goel; Felesia N Jones-MacFarland; William Ds Killgore; Frank Porreca; Mohab M Ibrahim
Journal:  Cephalalgia       Date:  2020-09-09       Impact factor: 6.292

4.  Strength and awareness in action: Feasibility of a yoga-based intervention for post-acute mild TBI headaches among veterans.

Authors:  Lisa M Betthauser; Jeri E Forster; Ann Bortz; Molly Penzenik; Theresa D Hernández; Nazanin Bahraini; Lisa A Brenner
Journal:  Contemp Clin Trials Commun       Date:  2021-04-02

5.  The efficacy of botulinum toxin type-A for intractable chronic migraine patients with no pain-free time.

Authors:  Dominic Atraszkiewicz; Rieko Ito; Anish Bahra
Journal:  Br J Pain       Date:  2021-05-24

6.  Comparative Effectiveness and Tolerability of the Pharmacology of Monoclonal Antibodies Targeting the Calcitonin Gene-Related Peptide and Its Receptor for the Prevention of Chronic Migraine: a Network Meta-analysis of Randomized Controlled Trials.

Authors:  Chun-Pai Yang; Bing-Yan Zeng; Ching-Mao Chang; Po-Hsuan Shih; Cheng-Chia Yang; Ping-Tao Tseng; Shuu-Jiun Wang
Journal:  Neurotherapeutics       Date:  2021-09-27       Impact factor: 6.088

7.  Psychological therapies for the prevention of migraine in adults.

Authors:  Louise Sharpe; Joanne Dudeney; Amanda C de C Williams; Michael Nicholas; Ingrid McPhee; Andrew Baillie; Miriam Welgampola; Brian McGuire
Journal:  Cochrane Database Syst Rev       Date:  2019-07-02

8.  Daily Headache in Chronic Migraine Is a Predictive Factor of Response in Patients Who Had Completed Three Sessions of OnabotulinumtoxinA.

Authors:  Enrique Martínez-Pías; Ángel L Guerrero; Álvaro Sierra; Javier Trigo; David García-Azorín
Journal:  Toxins (Basel)       Date:  2021-06-21       Impact factor: 4.546

9.  Feasibility of Smartphone-Delivered Progressive Muscle Relaxation in Persistent Post-Traumatic Headache Patients.

Authors:  Saima Usmani; Laura Balcer; Steven Galetta; Mia Minen
Journal:  J Neurotrauma       Date:  2020-08-26       Impact factor: 5.269

10.  MAB-MIG: registry of the spanish neurological society of erenumab for migraine prevention.

Authors:  Robert Belvís; Pablo Irimia; Patricia Pozo-Rosich; Carmen González-Oria; Antonio Cano; Javier Viguera; Belén Sánchez; Francisco Molina; Isabel Beltrán; Agustín Oterino; Elisa Cuadrado; Angel Gómez-Camello; Miguel Alberte-Woodward; Carmen Jurado; Teresa Oms; David Ezpeleta; Javier Díaz de Terán; Noemí Morollón; Germán Latorre; Marta Torres-Ferrús; Alicia Alpuente; Raquel Lamas; Carlos Toledano; Rogelio Leira; Sonia Santos; Margarita Sánchez Del Río
Journal:  J Headache Pain       Date:  2021-07-17       Impact factor: 7.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.